FDA Clears Silk Road’s Enroute Transcarotid Neuroprotection System
This article was originally published in The Gray Sheet
Executive Summary
The agency says it is the first such device designed to access the carotid arteries directly through an incision in the neck, instead of via a transfemoral catheter. Enroute reverses blood flow during carotid stenting or angioplasty to keep emboli away from the brain.
You may also be interested in...
Deals Of The Year: Cast Your Vote For Top Financing Of 2017
It's time for In Vivo's 10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
Japan Passes New Economic Security Bill – What's The Pharma Impact?
Japan has passed a new law which will require the providers of certain products to cooperate in securing supplies to the country. For the pharma industry, there are a couple of signs which specific drugs will be within the scope of the legislation and how this will impact the sector.
Hengrui’s PD-1 Camrelizumab Moves Step Closer To US Filing
Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.